Quantum BioPharma Ltd. (CSE:QNTM)
Canada
· Delayed Price · Currency is CAD 32.55
+3.90 (13.61%)
Jun 27, 2025, 9:30 AM EDT
Quantum BioPharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
Selling, General & Admin | 8.82 | 9.41 | 9.03 | 14.45 | 15.93 | 10.06 | Upgrade
|
Research & Development | 7.57 | 6.08 | 3.86 | 6.91 | 6.33 | 7.83 | Upgrade
|
Operating Expenses | 17.28 | 16.14 | 19.23 | 27.43 | 33.74 | 29.84 | Upgrade
|
Operating Income | -17.28 | -16.14 | -19.23 | -27.43 | -33.74 | -29.84 | Upgrade
|
Interest Expense | -0.37 | -0.03 | -0 | -0.05 | -0.07 | -0.24 | Upgrade
|
Interest & Investment Income | 0.47 | 0.57 | 0.79 | 0.37 | 0 | 0 | Upgrade
|
Other Non Operating Income (Expenses) | -5.32 | -0.05 | 0.21 | 0.52 | 0.68 | 2.56 | Upgrade
|
EBT Excluding Unusual Items | -22.5 | -15.64 | -18.24 | -26.59 | -33.13 | -27.51 | Upgrade
|
Gain (Loss) on Sale of Investments | -0 | -0 | -0.38 | -0.23 | -0.86 | -0.77 | Upgrade
|
Asset Writedown | - | - | -4.56 | - | - | -0.09 | Upgrade
|
Legal Settlements | - | - | - | - | - | -0.76 | Upgrade
|
Other Unusual Items | 0.94 | 0.73 | 4.94 | 0.12 | 0.05 | 0.68 | Upgrade
|
Pretax Income | -21.56 | -14.92 | -18.23 | -26.7 | -33.94 | -28.45 | Upgrade
|
Earnings From Continuing Operations | -21.56 | -14.92 | -18.23 | -26.7 | -33.94 | -28.45 | Upgrade
|
Earnings From Discontinued Operations | - | - | - | 3.1 | -1.35 | -3.35 | Upgrade
|
Net Income to Company | -21.56 | -14.92 | -18.23 | -23.61 | -35.29 | -31.8 | Upgrade
|
Minority Interest in Earnings | 0.69 | 0.71 | 0.33 | - | - | - | Upgrade
|
Net Income | -20.88 | -14.2 | -17.9 | -23.61 | -35.29 | -31.8 | Upgrade
|
Net Income to Common | -20.88 | -14.2 | -17.9 | -23.61 | -35.29 | -31.8 | Upgrade
|
Shares Outstanding (Basic) | 2 | 1 | 1 | 1 | 1 | 0 | Upgrade
|
Shares Outstanding (Diluted) | 2 | 1 | 1 | 1 | 1 | 0 | Upgrade
|
Shares Change (YoY) | 162.08% | 86.67% | 2.21% | 10.84% | 190.15% | 70.69% | Upgrade
|
EPS (Basic) | -13.02 | -12.49 | -29.39 | -39.62 | -65.63 | -171.62 | Upgrade
|
EPS (Diluted) | -13.02 | -12.49 | -29.39 | -39.62 | -65.63 | -171.62 | Upgrade
|
Free Cash Flow | -9.16 | -6.88 | -10.83 | -28.45 | -20.75 | -19.13 | Upgrade
|
Free Cash Flow Per Share | -5.72 | -6.05 | -17.78 | -47.74 | -38.59 | -103.25 | Upgrade
|
EBITDA | -16.78 | -15.65 | -16.73 | -22.9 | -29.7 | -25.94 | Upgrade
|
D&A For EBITDA | 0.5 | 0.49 | 2.51 | 4.53 | 4.05 | 3.9 | Upgrade
|
EBIT | -17.28 | -16.14 | -19.23 | -27.43 | -33.74 | -29.84 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.